A new partnership between the University of Oxford and GSK aims to develop vaccines against cancer before develop ...

Preclinical studies have demonstrated that vaccines targeting prostate and prostate cancer-associated antigens can induce immune responses to those antigens and result in protection from ...

mCRPC: Metastatic castration-resistant prostate cancer. Sipuleucel-T is the first therapeutic cancer vaccine approved by the US FDA, and is one of several new therapies available for treating ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Recent trends reveal a sharp rise in cancer cases in India, with younger patients and a lack of effective screening programs ...

It’s been 13 years since the FDA approved its first therapeutic vaccine – Dendreon Pharma’s Provenge (sipuleucel-T) for prostate cancer, which was not a commercial success – and since then ...

The BioInnovate UBC Annual Conference provides a unique platform for exploring emerging trends in biotechnology and fostering partnerships between academia and industry. Through an interactive panel ...

Part of that spike is due to rising rates of cancers that affect primarily women, including breast cancer and endometrial ...

Kennedy, President Donald Trump's pick to run the U.S. Department of Health and Human Services, Senate confirmation hearings ...

Cancer rates are declining, but young women are being diagnosed more frequently. Learn about the current trends and research ...

Scientists at a university in the UK are in the midst of creating a breakthrough vaccine that could stop cancer in its tracks ...